The earnings call reflects a strategic shift towards immunotherapy and government partnerships, which is promising. However, regulatory, competitive, and financial risks are significant, particularly with increased expenses and reliance on government funding. The Q&A section did not provide additional clarity, leaving uncertainties unresolved. While there are positive developments, such as internal manufacturing capabilities and increased cash reserves, these are offset by the risks and financial challenges. Therefore, the stock price is likely to remain stable in the short term, resulting in a neutral sentiment.